Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Adjuvant Treatment of Fully Resected Stage III Colon Cancer With FOLFOX-4 Versus FOLFOX-4 Plus Cetuximab

Trial Profile

Adjuvant Treatment of Fully Resected Stage III Colon Cancer With FOLFOX-4 Versus FOLFOX-4 Plus Cetuximab

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 11 Oct 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cetuximab (Primary) ; Fluorouracil; Folinic acid; Oxaliplatin
  • Indications Adenocarcinoma; Colon cancer
  • Focus Therapeutic Use
  • Acronyms PETACC-8
  • Most Recent Events

    • 09 Sep 2023 Results of post hoc pooled analysis (n=4548) from the PETACC-8 and International Duration Evaluation of Adjuvant chemotherapy (IDEA)-France trials looking at TTR depending on BRAF V6000E, RAS, and MMR status, and the impact of TTR on survival in general and specifically in these molecular subgroups, published in the European Journal of Cancer.
    • 16 Jan 2020 Results (n=6501) of pooled analysis of six clinical trials (NCT00079274; NCT00096278; NCT00004931; NCT00275210; NCT00265811; NCT00112918) examining the change of outcomes over 10-year period in patients with stage 3 colon cancer who were treated with fluorouracil, leucovorin, and oxaliplatin in the ACCENT database, published in the Annals of Oncology.
    • 09 Jun 2019 Trial has been completed in UK.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top